Quick Answer
REPLIGEN CORP reported Research And Development Expense of $54.18 million for the year ending 2025.
- REPLIGEN CORP showed an increase of +25.4% in Research And Development Expense from 2024 to 2025.
- This data is from REPLIGEN CORP's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), REPLIGEN CORP's Research And Development Expense has grown by 282.6%.
- Historical annual values: Fiscal year 2025: $54.18 million | Fiscal year 2024: $43.20 million | Fiscal year 2023: $42.72 million | Fiscal year 2022: $43.94 million | Fiscal year 2021: $34.27 million | Fiscal year 2020: $20.18 million | Fiscal year 2019: $19.45 million | Fiscal year 2018: $15.82 million | Fiscal year 2017: $8.67 million | Fiscal year 2016: $7.36 million | Fiscal year 2015: $5.74 million | Fiscal year 2014: $5.61 million | Fiscal year 2013: $7.34 million | Fiscal year 2012: $10.49 million | Fiscal year 2011: $12.53 million | Fiscal year 2010: $14.16 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: